RT Journal Article
T1 Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients-Results of a Spanish multicenter cohort.
A1 Lopez-Medrano, Francisco
A1 Silva, Jose Tiago
A1 Fernandez-Ruiz, Mario
A1 Vidal, Elisa
A1 Origüen, Julia
A1 Calvo-Cano, Antonia
A1 Luna-Huerta, Enrique
A1 Merino, Esperanza
A1 Hernandez, Domingo
A1 Jironda-Gallegos, Cristina
A1 Escudero, Rosa
A1 Gioia, Francesca
A1 Moreno, Antonio
A1 Roca, Cristina
A1 Cordero, Elisa
A1 Janeiro, Darío
A1 Sanchez-Sobrino, Beatriz
A1 Montero, Maria Milagro
A1 Redondo, Dolores
A1 Candel, Francisco Javier
A1 Perez-Flores, Isabel
A1 Armiñanzas, Carlos
A1 Gonzalez-Rico, Claudia
A1 Fariñas, Maria Carmen
A1 Rodrigo, Emilio
A1 Loeches, Belen
A1 Lopez-Oliva, Maria O
A1 Montejo, Miguel
A1 Lauzurica, Ricardo
A1 Horcajada, Juan Pablo
A1 Pascual, Julio
A1 Andres, Amado
A1 Aguado, Jose Maria
K1 Antibiotic
K1 Clinical research/practice
K1 Infection and infectious agents - bacterial
K1 Infectious disease
K1 Kidney transplantation/nephrology
AB Oral fosfomycin may constitute an alternative for the treatment of lower urinary tract infections (UTIs) in kidney transplant recipients (KTRs), particularly in view of recent safety concerns with fluroquinolones. Specific data on the efficacy and safety of fosfomycin in KTR are scarce. We performed a retrospective study in 14 Spanish hospitals including KTRs treated with oral fosfomycin (calcium and trometamol salts) for posttransplant cystitis between January 2005 and December 2017. A total of 133 KTRs developed 143 episodes of cystitis. Most episodes (131 [91.6%]) were produced by gram-negative bacilli (GNB), and 78 (54.5%) were categorized as multidrug resistant (including extended-spectrum β-lactamase-producing Enterobacteriaceae [14%] or carbapenem-resistant GNB [3.5%]). A median daily dose of 1.5 g of fosfomycin (interquartile range [IQR]: 1.5-2) was administered for a median of 7 days (IQR: 3-10). Clinical cure (remission of UTI-attributable symptoms at the end of therapy) was achieved in 83.9% (120/143) episodes. Among those episodes with follow-up urine culture, microbiological cure at month 1 was achieved in 70.2% (59/84) episodes. Percutaneous nephrostomy was associated with a lower probability of clinical cure (adjusted odds ratio: 10.50; 95% confidence interval: 0.98-112.29; P = 0.052). In conclusion, fosfomycin is an effective orally available alternative for treating cystitis among KTRs.
PB Elsevier
YR 2019
FD 2019-09-12
LK http://hdl.handle.net/10668/14542
UL http://hdl.handle.net/10668/14542
LA en
NO López-Medrano F, Silva JT, Fernández-Ruiz M, Vidal E, Origüen J, Calvo-Cano A, et al. Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients-Results of a Spanish multicenter cohort. Am J Transplant. 2020 Feb;20(2):451-462
NO This study was supported by Plan Nacional de I+D+i 2013‐2016 andInstituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016)—cofinanced by the European Development Regional Fund “A way to achieve Europe”; the Group for Study of Infection in Transplantation and the Immunocompromised Host (GESITRA‐IC) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC); and the Spanish Network for Research in Renal Diseases (REDInREN RD16/0009). MFR holds a researchcontract “Miguel Servet” (CP 18/00073) from the Spanish Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III. Funding sources had no involvement in the study design and conduction, data analysis, or manuscript preparation
DS RISalud
RD Apr 7, 2025